RedHill Biopharma Management
Management criteria checks 4/4
RedHill Biopharma's CEO is Dror Ben-Asher, appointed in Aug 2009, has a tenure of 15.5 years. total yearly compensation is $594.61K, comprised of 79.6% salary and 20.4% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $2.27K. The average tenure of the management team and the board of directors is 5.2 years and 13.8 years respectively.
Key information
Dror Ben-Asher
Chief executive officer
US$594.6k
Total compensation
CEO salary percentage | 79.6% |
CEO tenure | 15.5yrs |
CEO ownership | 0.03% |
Management average tenure | 5.2yrs |
Board average tenure | 13.8yrs |
Recent management updates
Recent updates
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate
Sep 10RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$30m |
Mar 31 2024 | n/a | n/a | -US$28m |
Dec 31 2023 | US$595k | US$473k | US$24m |
Sep 30 2023 | n/a | n/a | US$34m |
Jun 30 2023 | n/a | n/a | US$12m |
Mar 31 2023 | n/a | n/a | -US$900k |
Dec 31 2022 | US$865k | US$601k | -US$72m |
Sep 30 2022 | n/a | n/a | -US$92m |
Jun 30 2022 | n/a | n/a | -US$78m |
Mar 31 2022 | n/a | n/a | -US$95m |
Dec 31 2021 | US$1m | US$717k | -US$98m |
Sep 30 2021 | n/a | n/a | -US$98m |
Jun 30 2021 | n/a | n/a | -US$95m |
Mar 31 2021 | n/a | n/a | -US$82m |
Dec 31 2020 | US$817k | US$445k | -US$76m |
Sep 30 2020 | n/a | n/a | -US$64m |
Jun 30 2020 | n/a | n/a | -US$55m |
Mar 31 2020 | n/a | n/a | -US$50m |
Dec 31 2019 | US$708k | US$355k | -US$42m |
Sep 30 2019 | n/a | n/a | -US$38m |
Jun 30 2019 | n/a | n/a | -US$39m |
Mar 31 2019 | n/a | n/a | -US$39m |
Dec 31 2018 | US$576k | US$352k | -US$39m |
Compensation vs Market: Dror's total compensation ($USD594.61K) is about average for companies of similar size in the US market ($USD638.68K).
Compensation vs Earnings: Dror's compensation has been consistent with company performance over the past year.
CEO
Dror Ben-Asher (58 yo)
15.5yrs
Tenure
US$594,612
Compensation
Mr. Dror Ben-Asher Co-Founded at RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC.He has been affiliated wi...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 15.5yrs | US$594.61k | 0.031% $ 2.3k | |
Chief Financial Officer | 1.8yrs | US$354.22k | 0.013% $ 970.2 | |
Chief Operating Officer | 8.8yrs | US$379.96k | 0.019% $ 1.4k | |
Chief Corporate & Business Development Officer | 4.3yrs | US$353.70k | 0.021% $ 1.5k | |
Chief Commercial Officer | 6yrs | US$469.80k | 0.0089% $ 662.2 | |
Senior Business Development & Investor Relations Manager | 5.2yrs | no data | no data | |
Senior Vice President of Research & Development | 1.6yrs | US$419.98k | 0.014% $ 1.0k | |
Chief Business Officer | 12.6yrs | US$504.63k | 0.013% $ 953.1 | |
Senior Vice President of Regulatory Affairs | 1.6yrs | no data | no data |
5.2yrs
Average Tenure
54yo
Average Age
Experienced Management: RDHL's management team is seasoned and experienced (5.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 15.5yrs | US$594.61k | 0.031% $ 2.3k | |
Chief Commercial Officer | 9.1yrs | US$469.80k | 0.0089% $ 662.2 | |
Independent Director | 13.8yrs | no data | 0.0012% $ 87.0 | |
Member of Advisory Board | no data | no data | no data | |
Member of Advisory Board | no data | no data | no data | |
Member of Advisory Board | 6.1yrs | no data | no data | |
Member of Advisory Board | no data | no data | no data | |
Independent Director | 5.4yrs | no data | 0.041% $ 3.0k | |
Member of Advisory Board | no data | no data | no data | |
Independent Director | 14.8yrs | no data | 0.0095% $ 709.0 | |
Independent Director | 15.2yrs | no data | 0.061% $ 4.5k | |
Member of Advisory Board | no data | no data | no data |
13.8yrs
Average Tenure
67.5yo
Average Age
Experienced Board: RDHL's board of directors are seasoned and experienced ( 13.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/06 00:56 |
End of Day Share Price | 2025/02/06 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RedHill Biopharma Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Edward Woo | Ascendiant Capital Markets LLC |
null null | BTIG |
Brandon Folkes | Cantor Fitzgerald & Co. |